.Pharmacolibrary.Drugs.ATC.J.J01DI02 .Pharmacolibrary.Drugs.ATC.J.J01DI02| name: | CeftarolineFosamil |
| ATC code: | J01DI02 | route: | intravenous |
| n-compartments | 2 |
Ceftaroline fosamil is a broad-spectrum, fifth-generation cephalosporin antibiotic approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in adults and children. It is active against a range of Gram-positive and Gram-negative organisms, including methicillin-resistant Staphylococcus aureus (MRSA). The drug is administered as a prodrug (fosamil form), which is rapidly converted to the active ceftaroline in vivo.
Pharmacokinetic parameters in healthy adult subjects following intravenous administration.
Edlinger-Stanger, M, et al., & Hutschala, D (2021). Plasma and Lung Tissue Pharmacokinetics of Ceftaroline Fosamil in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: an . Antimicrobial agents and chemotherapy 65(10) e0067921–None. DOI:10.1128/AAC.00679-21 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34280013
Van Wart, SA, et al., & Ambrose, PG (2013). Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. Journal of clinical pharmacology 53(11) 1155–1167. DOI:10.1002/jcph.153 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23907740
Bradley, JS, et al., & Leister-Tebbe, HK (2020). Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis. The Pediatric infectious disease journal 39(5) 411–418. DOI:10.1097/INF.0000000000002607 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32091493